GSK agrees to buy US cancer drug firm Nuvalent in £8bn deal
Pharmaceutical giant GSK has agreed to buy US cancer drug firm Nuvalent in a $10.6bn (£8bn) deal as it looks to expand its cancer treatment offering.
GSK Acquires Nuvalent for $10.6 Billion
- GSK to buy US cancer treatment firm Nuvalent for $10.6bn The Guardian —
- GSK to buy US lung cancer drug specialist Nuvalent for £8bn The Argus —
- GSK to buy US lung cancer drug specialist Nuvalent for £8bn The Standard —
- GSK to buy US lung cancer drug specialist Nuvalent for £8bn The Independent —
- GSK just announced its biggest purchase in eight years to rev up cancer portfolio it had previously wound down MarketWatch —